The nation of Zimbabwe has declined a major US health deal worth $367m (£272m) over five years over Washington's demand for confidential information.
This rejection came to light following a government memo dated December was leaked, indicating that President Emmerson Mnangagwa felt the arrangement was "skewed".
A government spokesman has since clarified that the US was seeking biological samples for research and commercial purposes but was unwilling to share the benefits from any future medical innovations.
"We are forced to start the challenging and unfortunate task of scaling back our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had furnished more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has appealed for further dialogue to reach a deal agreeable to both sides so the nation's critical HIV programme can proceed.
Wider Context
This development comes after a comparable case in Kenya, where a high court halted a related deal with the US following legal challenges were raised about the safety of citizens' medical information.
Since returning to the presidency last year, US President Donald Trump has drastically cut overseas assistance and shut down the US Agency for International Development (USAID).
The agency had managed assistance for the American government, but Trump claimed its expenditure was "wasteful" and his government was seeking government-to-government deals to enhance openness and accountability.
According to reports, 16 nations in Africa have so far signed similar agreements, constituting over $18.3bn in new funding.
Specifics of the Declined Agreement
This assistance for Zimbabwe would have supported "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this collaboration could have provided immense benefits for Zimbabwean communities, especially the 1.2 million men, women and children presently receiving HIV treatment through US-supported programmes," the Ambassador added.
However, government spokesperson Nick Mangwana argued the arrangement was "unequal".
"The proposal required Zimbabwe to provide its biological resources and data for a long time, without any corresponding guarantee of benefiting from any scientific breakthroughs – like new medicines or tests – that could be developed from that provided information," his statement read.
"In essence, our nation would supply the basic resources for scientific discovery without any certainty that the final treatments would be accessible to our citizens if a future pandemic emerge."
Sovereignty and Global Health
Mangwana further noted that the American exit from the global health body and its push of one-on-one deals were disrupting frameworks previously established through the global health agency.
Mangwana cited its Pandemic Benefit-Sharing framework designed to manage potential pandemics.
"This framework is designed to ensure that when a country contributes its samples, the resulting advantages – such as medicines and cures – are distributed fairly, not commercialised solely by those with the funds to develop them."
These objections regarding the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We are open to ongoing discussions with our US partners on how subsequent collaboration might be designed in a way that honours the independence and dignity of each country."
Health Experts Reaction
A leading public health body stated it understood the official position, but recommended that talks must proceed given that a large portion of the country's Aids initiatives were funded by foreign aid.
"In cases where specific concerns arise, such as those involving information security or implementation frameworks, these can often be addressed via detailed discussion and mutually agreed protections," the group commented.
This impasse highlights the continuing challenges between accepting vital foreign assistance and protecting local interests in an ever more data-driven world.